Company Long-Term Loans and Borrowings: durect.com (DRRX)

Public company logo of DURECT (DRRX)

DURECT Corporation (DRRX) is a US-based biotechnology business specializing in the development of therapies for damaged organ recovery, leveraging its own proprietary substance delivery methods. Unique larsucosterol, capable of influencing genes and reducing mortality rates in hepatitis, provides significant market potential. The price trend on GURU.Markets, which stands at 0.00, underscores the company's dependence on liquidity due to a lack of profitable products and negative cash flow.

DRRX DURECT Corp Company Long-Term Debts (07/04/2022 - 09/27/2025)

Summary analytical data breakdowns for DURECT (DRRX)

- market price and analyst price targets:
Stock Price DURECT Corp|DRRX - Price Target Chart
- company stock exchange capitalization indicators:
Market Value DURECT|DRRX - Total Company Value
- book capitalization information:
Accounting Value per Share DURECT|DRRX - Book Capitalization|Market Capitalization to Book Value Ratio durect.com|DRRX - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio DURECT Corporation|DRRX - Long-Term Debt to Equity|Short-Term Debt to Equity DURECT Corp|DRRX - Company Aggregate Debts|Debts to Net Assets DURECT|DRRX - Company Long-Term Liabilities|Company Short-Term Debt DURECT|Immediate Liquidity durect.com
- earnings and multiples data:
DRRX - Company Net Income
Summary company analytics:DRRX DURECT Corporation
Brand item of DURECT Corp

For DURECT Corporation (DRRX), which is developing epigenetic regulators for the therapy of severe hepatitis, long-term debt defines the volume of obligations with maturities exceeding one year required to fund Phase 3 clinical trials. Analyzing the trend of the issuer's long-term liabilities allows for an assessment of the ratio between leverage and operational stability, where a reduction in debt load minimizes risks but may limit the pace of validation for the biotech pipeline.

Competitor analysis for DURECT Corporation

Company Long-Term Debts arrowheadpharma.com ARWR|MIRM - Company Long-Term Debt|Company Long-Term Loans and Borrowings DVAX (dynavax.com)|Arbutus (ABUS) - Company Long-Term Debt|Company Long-Term Liabilities Inventiva Corp|GYRE (Gyre Therapeutics, Inc.) - Company Long-Term Debts|Company Long-Term Debts assemblybio.com|Company Long-Term Liabilities GALT (Galectin Therapeutics)|GNFT (genfit.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Aligos Therapeutics, Inc. ALGS|BioVie Inc - Company Long-Term Debt|Galmed Pharma - Company Long-Term Debts|Long-Term Debt Volume endrainc.com NDRA|HEPA (hepionpharma.com) - Company Long-Term Liabilities